abs39.txt	objective		recent	evidence	suggests	the	Î±2-adrenoreceptor	agonist	dexmedetomidinemay	promote	metastasis	of	cancer	cells		in	this	study	we	sought	to	evaluate	theimpact	of	dexmedetomidine	administration	on	the	survival	of	children	andadolescents	with	cancer	design		retrospective	chart	review	setting		comprehensive	cancer	center	patients		children	and	adolescents	who	had	undergone	cytoreductive	surgery	withhyperthermic	intraperitoneal	chemotherapy	for	peritoneal	carcinomatosis	intervention		intraoperative	and/or	early	postoperative	(within	24	hours	ofsurgery)	administration	of	dexmedetomidine	measurements		multivariable	cox	proportional	hazard	models	were	used	to	assessthe	association	between	dexmedetomidine	administration	and	progression	freesurvival	(pfs)	or	overall	survival	(os)	main	results		ninety-three	patients	were	identified		the	median	age	was	12	years	42%	were	female		and	35%	received	dexmedetomidine		there	were	no	significantdifferences	between	the	baseline	and	perioperative	characteristics	of	patientswho	received	dexmedetomidine	and	those	who	did	not		in	the	multivariableanalysis		the	administration	of	dexmedetomidine	was	not	associated	with	pfs(hr	=	1	20		95%	ci	[0	60-2	41]		p	=		606)	or	os	(hr	=	0	81		95%	ci	[0	35-1	85]	p	=		611)	conclusion		in	this	retrospective	study	of	children	and	adolescents	who	hadundergone	a	major	oncologic	surgery		the	intraoperative	and/or	earlypostoperative	administration	of	dexmedetomidine	was	not	associated	with	survival	
